哮喘诊断与治疗概要.ppt

Symbicort AMD旨在在正确的时间提供正确的治疗剂量 Symbicort AMD与每日两次固定剂量治疗相比，降低了哮喘病人的急性发作病例数； 在较低的平均剂量负荷下仍然有效； 与现在的哮喘治疗指南相吻合。 Symbicort AMD 结论 Symbicort AMD旨在在正确的时间提供正确的剂量； AMD在针对哮喘控制的变化中，与FD相比较，能够在较低的总剂量负荷下，达到更好的结果； AMD 与FD相比较，降低了哮喘急性发作的病例数； AMD在较低的剂量负荷下同样有效； AMD与现在的哮喘治疗指南相吻合。 * Slide 4 - Airway inflammation can be classified into acute and chronic events. Acute inflammation develops and reverses rapidly as the result of cell activation and mediator release. Chronic inflammation is more persistent and is orchestrated by increased numbers of inflammatory cells resident in airway tissue. * Slide 3 - The smooth muscle dysfunction component involves an increased smooth muscle mass and release of inflammatory mediators. The result is exaggerated smooth muscle contraction and increased bronchoconstriction. * Slide 6 - The pathophysiogical consequences of airway inflammation is remodelling and airway narrowing, increased bronchial reactivity and reduced reversibility. This leads to the clinical manifestations of the disease - intermittent symptoms and prolonged periods of exacerbations. * Slide 5 - Airway remodelling results in permanent changes to airway structure. It is characterised by cellular proliferation, matrix protein deposition and angiogenesis. * 1，局部和中枢神经系统的神经反射增加；2，表现为表面活性物质分泌和功能的改变；3，粘膜下肿胀、炎症和基质沉积；4，分布在广泛表面区域的肺泡的伸缩力；5，平滑肌增生和功能改变。 * Despite the many recent advances in diagnosis and treatment, asthma-related morbidity and mortality continue to affect both adults and children. Although this is partly due to suboptimal use of existing asthma therapies, it is clear that even when such therapy is optimized, it may not completely control symptoms and prevent progression of disease. This highlights the need for a disease modifier—a form of treatment that alters the natural course of the disease. A true disease modifier has not yet been identified, but as more is learned about the immune/inflammatory processes that underlie asthma symptoms (shown in this schematic illustration), ne